IMM Immupharma Plc

 

TIDMIMM 
 
RNS Number : 4164T 
Immupharma PLC 
28 September 2010 
 

 
+--------------------------------------------+----------------------+ 
| For Immediate Release                      |    28 September 2010 | 
+--------------------------------------------+----------------------+ 
 
 
                                 ImmuPharma PLC 
 
                        Notification of Interim Results 
 
ImmuPharma PLC (AIM:IMM), the specialist drug discovery and development company, 
is scheduled to announce its Interim Results for the six months ended 30 June 
2010 on Thursday 30th September 2010. 
 
 
For further information please contact: 
 
+----------------------------------+--------------------------+ 
| ImmuPharma PLC:                  |                          | 
+----------------------------------+--------------------------+ 
| Dimitri Dimitriou, Chief         |         +44 20 7152 4080 | 
| Executive Officer                |                          | 
+----------------------------------+--------------------------+ 
| Dr Robert Zimmer, President &    |        + 33 389 32 76 50 | 
| Chief Scientific Officer         |                          | 
+----------------------------------+--------------------------+ 
| Richard Warr, Chairman           |         +44 20 7152 4080 | 
+----------------------------------+--------------------------+ 
|                                  |                          | 
+----------------------------------+--------------------------+ 
| Buchanan Communications          |        + 44 20 7466 5000 | 
+----------------------------------+--------------------------+ 
| Lisa Baderoon                    |                          | 
+----------------------------------+--------------------------+ 
| Mark Court                       |                          | 
+----------------------------------+--------------------------+ 
| George Prassas                   |                          | 
+----------------------------------+--------------------------+ 
 
+----------------------------------+--------------------------+----------+ 
| Panmure Gordon & Co (NOMAD &     |                   + 44 20 7459 3600 | 
| Broker)                          |                                     | 
+----------------------------------+-------------------------------------+ 
| Andrew Burnett                   |                                     | 
+----------------------------------+-------------------------------------+ 
| Rakesh Sharma                    |                                     | 
+----------------------------------+-------------------------------------+ 
|                                  |                          |          | 
+----------------------------------+--------------------------+----------+ 
| Execution Noble (Joint Broker)   |                          |          | 
+----------------------------------+--------------------------+----------+ 
| James Bromhead                   |        + 44 20 7456 9191 |          | 
+----------------------------------+--------------------------+----------+ 
| Richard Crawley                  |                          |          | 
+----------------------------------+--------------------------+----------+ 
 
 
Notes to Editors: 
 
About ImmuPharma 
 
ImmuPharma PLC is a drug discovery and development company headquartered in 
London, UK and quoted on AIM of the London Stock Exchange (LSE:IMM). It has 
research operations in France (ImmuPharma (France) SA) and Switzerland 
(ImmuPharma AG). ImmuPharma is dedicated to the development of novel drugs, 
largely based on peptide therapeutics, to treat serious medical conditions such 
as autoimmune diseases characterised by: 
 
·      blockbuster potential in niche markets 
 
·      low promotional costs in few specialised physicians and centres and 
 
·      lower risk of drug development and lower development costs 
 
ImmuPharma is a currently developing drug candidates for three different medical 
conditions, each of which would represent a significant breakthrough in its 
field. The furthest advanced drug candidate targets Lupus, a disease for which 
there is currently no cure or specific treatment. The other two address moderate 
to severe pain (such as that experienced by cancer sufferers and post-operative 
patients), and MRSA and similar severe hospital-acquired resistant infections. 
 
All three have significant sales potential as well as low marketing costs and a 
relatively low risk of development failure. One or more have the potential to be 
fast-tracked by the US Food and Drug Administration according to "Guidance for 
Industry: Fast Track Drug Development Programs - Designation, Development and 
Application Review" issued July 2004 and could therefore obtain their market 
authorization by 2010. 
 
Key to the potential success of ImmuPharma is its unique collaborative agreement 
with Centre National de la Recherche Scientifique, France's scientific research 
institution. This agreement grants ImmuPharma worldwide exclusive rights to 
exploit certain key discoveries. 
 
In addition to its three leading drug candidates, ImmuPharma has a drug 
development pipeline using its rights to a virtual chemical library of hundreds 
of thousands of molecules as well as an innovative technology for converting 
peptides to drug candidates. 
 
ImmuPharma has the option to commercialise its assets itself or to license them 
to other pharmaceutical companies at an earlier stage. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NORKVLBLBKFFBBQ 
 

Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024

Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024